Literature DB >> 20568780

(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators.

Shiv K Sharma1, Yu Wu, Nora Steinbergs, Michael L Crowley, Allison S Hanson, Robert A Casero, Patrick M Woster.   

Abstract

The recently discovered enzyme lysine-specific demethylase 1 (LSD1) plays an important role in the epigenetic control of gene expression, and aberrant gene silencing secondary to LSD1 overexpression is thought to contribute to the development of cancer. We recently reported a series of (bis)guanidines and (bis)biguanides that are potent inhibitors of LSD1 and induce the re-expression of aberrantly silenced tumor suppressor genes in tumor cells in vitro. We now report a series of isosteric ureas and thioureas that are also potent inhibitors of LSD1. These compounds induce increases in methylation at the histone 3 lysine 4 (H3K4) chromatin mark, a specific target of LSD1, in Calu-6 lung carcinoma cells. In addition, these analogues increase cellular levels of secreted frizzle-related protein (SFRP) 2 and transcription factor GATA4. These compounds represent an important new series of epigenetic modulators with the potential for use as antitumor agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20568780      PMCID: PMC2920492          DOI: 10.1021/jm100217a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  48 in total

Review 1.  Histone methylation in transcriptional control.

Authors:  Tony Kouzarides
Journal:  Curr Opin Genet Dev       Date:  2002-04       Impact factor: 5.578

Review 2.  Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails.

Authors:  Y Zhang; D Reinberg
Journal:  Genes Dev       Date:  2001-09-15       Impact factor: 11.361

Review 3.  Translating the histone code.

Authors:  T Jenuwein; C D Allis
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

Review 4.  Gene silencing in cancer in association with promoter hypermethylation.

Authors:  James G Herman; Stephen B Baylin
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

5.  Properties of purified recombinant human polyamine oxidase, PAOh1/SMO.

Authors:  Yanlin Wang; Tracy Murray-Stewart; Wendy Devereux; Amy Hacker; Benjamin Frydman; Patrick M Woster; Robert A Casero
Journal:  Biochem Biophys Res Commun       Date:  2003-05-16       Impact factor: 3.575

Review 6.  Unsafe SETs: histone lysine methyltransferases and cancer.

Authors:  Robert Schneider; Andrew J Bannister; Tony Kouzarides
Journal:  Trends Biochem Sci       Date:  2002-08       Impact factor: 13.807

7.  Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome.

Authors:  Gangning Liang; Joy C Y Lin; Vivian Wei; Christine Yoo; Jonathan C Cheng; Carvell T Nguyen; Daniel J Weisenberger; Gerda Egger; Daiya Takai; Felicidad A Gonzales; Peter A Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

Review 8.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.

Authors:  Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

9.  Histone H3 lysine 4 methylation patterns in higher eukaryotic genes.

Authors:  Robert Schneider; Andrew J Bannister; Fiona A Myers; Alan W Thorne; Colyn Crane-Robinson; Tony Kouzarides
Journal:  Nat Cell Biol       Date:  2003-12-07       Impact factor: 28.824

10.  Molecular basis for the binding of competitive inhibitors of maize polyamine oxidase.

Authors:  Alessandra Cona; Fabrizio Manetti; Rosalida Leone; Federico Corelli; Paraskevi Tavladoraki; Fabio Polticelli; Maurizio Botta
Journal:  Biochemistry       Date:  2004-03-30       Impact factor: 3.162

View more
  45 in total

1.  Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.

Authors:  Pravin Bhansali; Christin L Hanigan; Robert A Casero; L M Viranga Tillekeratne
Journal:  J Med Chem       Date:  2011-10-10       Impact factor: 7.446

2.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.

Authors:  Tino Schenk; Weihsu Claire Chen; Stefanie Göllner; Louise Howell; Liqing Jin; Katja Hebestreit; Hans-Ulrich Klein; Andreea C Popescu; Alan Burnett; Ken Mills; Robert A Casero; Laurence Marton; Patrick Woster; Mark D Minden; Martin Dugas; Jean C Y Wang; John E Dick; Carsten Müller-Tidow; Kevin Petrie; Arthur Zelent
Journal:  Nat Med       Date:  2012-03-11       Impact factor: 53.440

Review 3.  Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.

Authors:  Zhanxin Wang; Dinshaw J Patel
Journal:  Q Rev Biophys       Date:  2013-09-02       Impact factor: 5.318

4.  Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures.

Authors:  Shannon L Nowotarski; Boobalan Pachaiyappan; Steven L Holshouser; Craig J Kutz; Youxuan Li; Yi Huang; Shiv K Sharma; Robert A Casero; Patrick M Woster
Journal:  Bioorg Med Chem       Date:  2015-02-07       Impact factor: 3.641

5.  Histone demethylases and their roles in cancer epigenetics.

Authors:  Alexandra D'Oto; Qing-Wu Tian; Andrew M Davidoff; Jun Yang
Journal:  J Med Oncol Ther       Date:  2016

6.  Discovery of novel alkylated (bis)urea and (bis)thiourea polyamine analogues with potent antimalarial activities.

Authors:  Bianca K Verlinden; Jandeli Niemand; Janette Snyman; Shiv K Sharma; Ross J Beattie; Patrick M Woster; Lyn-Marie Birkholtz
Journal:  J Med Chem       Date:  2011-09-14       Impact factor: 7.446

Review 7.  KDM1 class flavin-dependent protein lysine demethylases.

Authors:  Jonathan M Burg; Jennifer E Link; Brittany S Morgan; Frederick J Heller; Amanda E Hargrove; Dewey G McCafferty
Journal:  Biopolymers       Date:  2015-07       Impact factor: 2.505

8.  Discovery of [1,2,3]Triazolo[4,5-d]pyrimidine Derivatives as Novel LSD1 Inhibitors.

Authors:  Zhong-Hua Li; Xue-Qi Liu; Peng-Fei Geng; Feng-Zhi Suo; Jin-Lian Ma; Bin Yu; Tao-Qian Zhao; Zhao-Qing Zhou; Chen-Xi Huang; Yi-Chao Zheng; Hong-Min Liu
Journal:  ACS Med Chem Lett       Date:  2017-03-06       Impact factor: 4.345

Review 9.  Mechanisms and metabolic implications of regional differences among fat depots.

Authors:  Tamara Tchkonia; Thomas Thomou; Yi Zhu; Iordanes Karagiannides; Charalabos Pothoulakis; Michael D Jensen; James L Kirkland
Journal:  Cell Metab       Date:  2013-04-11       Impact factor: 27.287

10.  3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.

Authors:  Fangrui Wu; Chao Zhou; Yuan Yao; Liping Wei; Zizhen Feng; Lisheng Deng; Yongcheng Song
Journal:  J Med Chem       Date:  2015-12-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.